Time-restricted eating combined with GLP-1RAs significantly reduced nighttime glucose and HbA1c in Type 2 Diabetes

Poorly controlled Type 2 Diabetes Mellitus (T2DM), characterized by insulin resistance and impaired blood glucose regulation, significantly increases the risk of serious complications. A critical, often overlooked, aspect is elevated nighttime glucose, which is strongly linked to higher cardiometabolic disorder risk. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized T2DM management by improving glycemic control and offering cardiovascular benefits, some patients still struggle with nocturnal hyperglycemia. Time-restricted eating (TRE), a lifestyle intervention aligning food intake with the circadian system (typically an 8- to 10-hour eating window), has shown promise in improving cardiovascular health and glycemic control, suggesting it could offer additional benefits beyond stable GLP-1RA use.

This case series involved 3 patients with Type 2 Diabetes Mellitus (T2DM) who were already on stable GLP-1RA therapy. Participants were instructed to follow a consistent 8- to 10-hour time-restricted eating (TRE) intervention daily for 3 months. At baseline, all patients exhibited high mean glucose levels (>130 mg/dL) during nightly sleep. Assessments, including fasted blood draws for hemoglobin A1c (HbA1c), 10-day continuous glucose monitor (CGM) use to track glucose levels, and 14-day actigraphy to measure sleep-wake cycles, were conducted at both baseline and after the 3-month intervention period. The study aimed to observe the impact of TRE on glycemic control and sleep patterns in this specific population.

Following the 3-month time-restricted eating (TRE) intervention, all 3 patients on stable GLP-1RA therapy experienced notable improvements in key glycemic markers. Specifically, reductions were observed in hemoglobin A1c (HbA1c) levels across all participants, indicating improved long-term glycemic control. Furthermore, nighttime glucose levels, which were initially high (mean >130 mg/dL) at baseline, also decreased in all 3 patients. This reduction in nocturnal hyperglycemia is particularly significant given its association with cardiometabolic risk. The intervention also led to improved time in range (TIR) during sleep for all 3 patients, suggesting more stable and healthier glucose profiles throughout the night. The abstract emphasizes the potential of CGM to identify specific glycemic phenotypes that might predict individual responses to TRE, highlighting the importance of a personalized approach. This case series strongly suggests that TRE can provide additional benefits even when combined with established GLP-1RA regimens.

All 3 patients experienced reductions in hemoglobin A1c (HbA1c) and nighttime glucose, along with improved time in range (TIR) during sleep after 3 months of time-restricted eating.